Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kelcie Waack

Internal Medicine Southgate, MI Nurse Practitioner

NPI 1730762246 CMS profile 9127133

3 Heritage Center, Southgate, MI 48195

Open in the dashboard

General payments

$5,275

288 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelcie Waack of Southgate, MI is reported in the CMS Open Payments database as having received $5,275 across 288 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,590 81
2024 General $1,843 103
2023 General $1,180 64
2022 General $478 29
2021 General $184 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelcie Waack
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kelcie Waack were reported at $1,590. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kelcie Waack Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $184 $135 $37–$521 $132
2022 $478 $141 $42–$496 $149
2023 $1,180 $149 $45–$519 $160
2024 $1,843 $154 $47–$537 $164
2025 $1,590 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,024 50 payments
  2. Lilly USA, LLC $537 37 payments
  3. Shionogi Inc $374 14 payments
  4. Novo Nordisk Inc $372 23 payments
  5. Otsuka America Pharmaceutical, Inc. $304 15 payments
  6. Pfizer Inc. $220 12 payments
  7. Novartis Pharmaceuticals Corporation $201 12 payments
  8. AstraZeneca Pharmaceuticals LP $183 12 payments
  9. Aimmune Therapeutics, Inc. $177 9 payments
  10. GlaxoSmithKline, LLC. $157 10 payments
  11. Other $1,725 94 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,275 288 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $487 22 payments
  2. MOUNJARO $382 28 payments
  3. Fetroja $374 14 payments
  4. Ozempic $343 21 payments
  5. RYBELSUS $313 20 payments
  6. REXULTI $304 15 payments
  7. LEQVIO $186 11 payments
  8. NURTEC ODT $181 10 payments
  9. QULIPTA $175 9 payments
  10. ZENPEP $172 8 payments
  11. Other $3,794 215 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 106 drugs

Part D claims

3,737

Median for Internal Medicine: 777

Drug cost

$396,864

Median for Internal Medicine: $73,373

Branded share of claims

30%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 79 $92,202
Zenpep Lipase/Protease/Amylase Brand 12 $59,696
Jardiance Empagliflozin Brand 32 $35,049
Ozempic Semaglutide Brand 26 $29,135
Farxiga Dapagliflozin Propanediol Brand 20 $27,204
Trulicity Dulaglutide Brand 16 $18,908
Eliquis Apixaban Brand 12 $17,411
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 23 $14,422
Tresiba Flextouch U-100 Insulin Degludec Brand 15 $12,378
Breo Ellipta Fluticasone/Vilanterol Brand 23 $10,658

The 10 drugs with the highest cost, of 106 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $201
$201 — —
Fetroja
  • Shionogi Inc $178
$178 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $106
  • Lundbeck LLC $53
$159 — —
MOUNJARO
  • Lilly USA, LLC $144
$144 79 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $55
  • Lilly USA, LLC $42
$97 32 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

288 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record